ES2904570T3 - Formulación de DHE intranasal para el tratamiento del dolor de cabeza - Google Patents
Formulación de DHE intranasal para el tratamiento del dolor de cabeza Download PDFInfo
- Publication number
- ES2904570T3 ES2904570T3 ES14830861T ES14830861T ES2904570T3 ES 2904570 T3 ES2904570 T3 ES 2904570T3 ES 14830861 T ES14830861 T ES 14830861T ES 14830861 T ES14830861 T ES 14830861T ES 2904570 T3 ES2904570 T3 ES 2904570T3
- Authority
- ES
- Spain
- Prior art keywords
- dhe
- powder formulation
- formulation
- minutes
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881947P | 2013-09-24 | 2013-09-24 | |
| PCT/IB2014/002706 WO2015044782A2 (en) | 2013-09-24 | 2014-09-24 | Intranasal dhe for the treatment of headache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2904570T3 true ES2904570T3 (es) | 2022-04-05 |
Family
ID=52424045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14830861T Active ES2904570T3 (es) | 2013-09-24 | 2014-09-24 | Formulación de DHE intranasal para el tratamiento del dolor de cabeza |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US20160228433A1 (enExample) |
| EP (2) | EP3049059B1 (enExample) |
| JP (2) | JP2016531850A (enExample) |
| DK (1) | DK3049059T3 (enExample) |
| ES (1) | ES2904570T3 (enExample) |
| WO (1) | WO2015044782A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101980738A (zh) | 2008-02-07 | 2011-02-23 | 华盛顿大学 | 圆周气雾设备 |
| EP2680913B1 (en) | 2011-03-03 | 2020-05-06 | Impel NeuroPharma Inc. | Nasal drug delivery device |
| CN107376071B (zh) | 2011-05-09 | 2021-07-09 | 英倍尔药业股份有限公司 | 用于将化合物递送到使用者的上部嗅觉区的喷嘴 |
| HK1222358A1 (zh) | 2013-04-28 | 2017-06-30 | Impel Neuropharma Inc. | 医用单位剂量容器 |
| EP3049059B1 (en) | 2013-09-24 | 2021-11-03 | Satsuma Pharmaceuticals, Inc. | Intranasal dhe formulation for the treatment of headache |
| EP3341059B1 (en) | 2015-09-10 | 2022-03-02 | Impel NeuroPharma Inc. | In-line nasal delivery device |
| CA3030359A1 (en) | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| BR112019027508A2 (pt) * | 2017-07-02 | 2020-07-07 | Dr. Reddys Laboratories Limited | formas de dosagem nasal de di-hidroergotamina |
| US11571532B2 (en) | 2017-11-21 | 2023-02-07 | Impel Pharmaceuticals Inc. | Intranasal device with dip tube |
| US11395887B2 (en) | 2017-11-21 | 2022-07-26 | Impel Pharmaceuticals Inc. | Intranasal device with inlet interface |
| EP3735223A4 (en) | 2018-01-05 | 2021-10-13 | Impel Neuropharma Inc. | INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE |
| BR112020013744A8 (pt) * | 2018-01-05 | 2022-10-18 | Impel Neuropharma Inc | Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão |
| JP2021532098A (ja) | 2018-07-19 | 2021-11-25 | インペル ニューロファーマ インコーポレイテッド | パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達 |
| CA3122396A1 (en) | 2018-12-11 | 2020-06-18 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
| CN113473967B (zh) | 2019-01-03 | 2022-09-09 | 英倍尔制药公司 | 经鼻药物递送装置 |
| AU2020277313A1 (en) | 2019-05-17 | 2022-01-20 | Impel Pharmaceuticals Inc. | Single-use nasal delivery device |
| IL324950A (en) * | 2023-05-31 | 2026-01-01 | Shin Nippon Biomedical Laboratories Ltd | Compositions for enhanced mucosal penetration |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2750090A1 (de) | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
| US5169849A (en) * | 1982-02-01 | 1992-12-08 | Sandoz Ltd. | Nasal pharmaceutical compositions |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| DE69434304T2 (de) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin |
| JP3197221B2 (ja) * | 1996-02-27 | 2001-08-13 | 帝人株式会社 | 吸収性が改善された粉末状経鼻投与組成物 |
| SE9803770D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Ab | Dry powder pharmaceutical formulation |
| AU7685200A (en) * | 1999-10-12 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Powdery inhalational preparations and process for producing the same |
| EP1397173A1 (en) * | 2001-06-20 | 2004-03-17 | Nektar Therapeutics | Powder aerosolization apparatus and method |
| MXPA03005980A (es) * | 2001-07-05 | 2003-09-10 | Translational Res Ltd | Composiciones para administracion nasal de insulina. |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| JP4212019B2 (ja) * | 2002-01-09 | 2009-01-21 | Translational Research 株式会社 | 薬物の経鼻投与用組成物 |
| GB0228826D0 (en) * | 2002-12-11 | 2003-01-15 | Okpala Joseph | Hair technology in creating particles with improved delivery capabilities |
| US7638138B2 (en) * | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
| GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
| EP1663159A4 (en) | 2003-09-10 | 2010-06-09 | Map Pharmaceuticals Inc | AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION |
| WO2006016530A1 (ja) * | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
| JP5694643B2 (ja) * | 2005-08-05 | 2015-04-01 | スリーエム イノベイティブ プロパティズ カンパニー | 改善された流動性を示す組成物 |
| WO2007066646A1 (ja) * | 2005-12-06 | 2007-06-14 | Asahi Kasei Chemicals Corporation | 高速直接打錠による錠剤の製造方法 |
| ES2652415T3 (es) * | 2006-12-26 | 2018-02-02 | Shin Nippon Biomedical Laboratories, Ltd. | Preparación para aplicación transnasal |
| PL2425820T3 (pl) | 2007-02-11 | 2015-08-31 | Map Pharmaceuticals Inc | Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych |
| JP2009076785A (ja) * | 2007-09-21 | 2009-04-09 | Panasonic Corp | 半導体装置の製造方法 |
| US20110082150A1 (en) | 2008-02-11 | 2011-04-07 | Robert Owen Cook | Headache pre-emption by dihydroergotamine treatment during headache Precursor events |
| US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| US20110171141A1 (en) * | 2009-06-26 | 2011-07-14 | Kellerman Donald J | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| US8827946B2 (en) | 2009-07-31 | 2014-09-09 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| SG181896A1 (en) | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
| EP2689785B1 (en) * | 2010-04-15 | 2021-05-19 | Shin Nippon Biomedical Laboratories, Ltd. | Method for generating dry vaccine powder formulation for inranasal delivery |
| WO2011163600A2 (en) * | 2010-06-25 | 2011-12-29 | Apt Pharmaceuticals, Inc. | Tacrolimus compositions for aerosol administration |
| ES2659761T3 (es) | 2011-01-31 | 2018-03-19 | Shin Nippon Biomedical Laboratories, Ltd. | Dispositivos de administración intranasal |
| EP2680913B1 (en) | 2011-03-03 | 2020-05-06 | Impel NeuroPharma Inc. | Nasal drug delivery device |
| EP2787970B1 (en) * | 2011-12-11 | 2018-04-11 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| US20140179705A1 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
| EP2935280A4 (en) | 2012-12-21 | 2016-05-25 | Map Pharmaceuticals Inc | 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS |
| EP3049059B1 (en) | 2013-09-24 | 2021-11-03 | Satsuma Pharmaceuticals, Inc. | Intranasal dhe formulation for the treatment of headache |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| CA3030359A1 (en) | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| JP7523879B2 (ja) | 2016-10-31 | 2024-07-29 | エスエス製薬株式会社 | 医薬組成物 |
| BR112019027508A2 (pt) | 2017-07-02 | 2020-07-07 | Dr. Reddys Laboratories Limited | formas de dosagem nasal de di-hidroergotamina |
| US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
| BR112020013744A8 (pt) | 2018-01-05 | 2022-10-18 | Impel Neuropharma Inc | Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão |
| CA3122396A1 (en) | 2018-12-11 | 2020-06-18 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
-
2014
- 2014-09-24 EP EP14830861.2A patent/EP3049059B1/en active Active
- 2014-09-24 JP JP2016516520A patent/JP2016531850A/ja active Pending
- 2014-09-24 DK DK14830861.2T patent/DK3049059T3/da active
- 2014-09-24 EP EP21205407.6A patent/EP4008307A1/en active Pending
- 2014-09-24 US US15/023,206 patent/US20160228433A1/en not_active Abandoned
- 2014-09-24 WO PCT/IB2014/002706 patent/WO2015044782A2/en not_active Ceased
- 2014-09-24 ES ES14830861T patent/ES2904570T3/es active Active
-
2019
- 2019-05-16 US US16/414,350 patent/US20190275036A1/en not_active Abandoned
- 2019-09-06 JP JP2019162995A patent/JP6902583B2/ja active Active
-
2020
- 2020-02-14 US US16/791,431 patent/US20200179379A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,583 patent/US12594273B2/en active Active
-
2023
- 2023-10-02 US US18/479,335 patent/US20240108619A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230000860A1 (en) | 2023-01-05 |
| JP6902583B2 (ja) | 2021-07-14 |
| US20240108619A1 (en) | 2024-04-04 |
| EP4008307A1 (en) | 2022-06-08 |
| JP2020007342A (ja) | 2020-01-16 |
| US20200179379A1 (en) | 2020-06-11 |
| US20160228433A1 (en) | 2016-08-11 |
| WO2015044782A2 (en) | 2015-04-02 |
| WO2015044782A3 (en) | 2015-06-11 |
| JP2016531850A (ja) | 2016-10-13 |
| US12594273B2 (en) | 2026-04-07 |
| DK3049059T3 (da) | 2022-01-31 |
| EP3049059A2 (en) | 2016-08-03 |
| EP3049059B1 (en) | 2021-11-03 |
| US20190275036A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12594273B2 (en) | Intranasal DHE for the treatment of headache | |
| ES2660116T3 (es) | Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina | |
| TW202116304A (zh) | 非鎮靜之右美托咪啶(dexmedetomidine)治療方案 | |
| ES2882530T3 (es) | Partículas finas de epinefrina y métodos para uso de las mismas para el tratamiento de condiciones que responden a la epinefrina | |
| WO2018035393A1 (en) | Methods of treating eosinophilic esophagitis | |
| JP2019520361A (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
| EP2793857B1 (en) | Drug delivery technology | |
| BRPI0610187B1 (pt) | Tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo | |
| DK2838510T3 (en) | Atomoxetine solution | |
| EP3538189A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| US20250302741A1 (en) | Intranasal olanzapine formulations and methods of their use | |
| AU2011253775B2 (en) | Compositions and Methods for Increasing Blood Platelet Levels in Humans | |
| JP2022514340A (ja) | 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法 | |
| ES2763321T3 (es) | Premezcla y composición farmacéutica para la administración oral de memantina como una suspensión permanente o de preparación previa a la administración al paciente, optativamente por sonda de alimentación enteral y procedimientos correspondientes | |
| HK40076888A (en) | Intranasal dhe formulation for the treatment of headache | |
| WO2022074630A1 (en) | Liquid oral suspension of favipiravir | |
| CN116801863A (zh) | 右美托咪定治疗方案 | |
| RS65089B1 (sr) | Tečna kompozicija koja sadrži ibuprofen i fenilefrin | |
| HK1233158B (en) | Intranasal dhe formulation for the treatment of headache | |
| HK1170673B (en) | Compositions and methods for increasing blood platelet levels in humans |